AAV Vectors Cannot Package Genes Larger Than 4.7 kb, Excluding Major Genetic Diseases

The most commonly used gene therapy delivery vehicle (AAV) can only carry ~4,700 base pairs of DNA. But many serious diseases involve much larger genes: dystrophin for Duchenne muscular dystrophy is 14 kb, CFTR for cystic fibrosis needs ~6 kb with regulatory elements, ABCA4 for Stargardt disease is 6.8 kb.

AAV's icosahedral capsid constrains payload to ~4.7 kb including ITRs. Dual-AAV strategies (splitting transgene across two vectors) achieve only 5-20% of single-vector expression. Sarepta's Elevidys (conditionally approved 2023, $3.2M/patient) uses truncated micro-dystrophin (~3.6-4.2 kb) that lacks key spectrin-like repeats and shows mixed efficacy in confirmatory trials. Helper-dependent adenovirus and HSV vectors have larger capacity but worse immunogenicity and persistence profiles.

Why It Matters

DMD affects 1 in 3,500-5,000 males (~300,000 globally). CF affects ~100,000 worldwide. Stargardt disease: 1 in 8,000-10,000. Elevidys at $3.2M/patient uses truncated gene because full-length doesn't fit — and shows mixed results precisely because of this truncation.

Startup Approach

Develop non-viral delivery systems (LNPs, VLPs) with larger cargo capacity. Or engineer more efficient dual-AAV reconstitution strategies approaching single-vector expression. The mRNA/LNP revolution proved non-viral delivery at scale is possible — apply to DNA cargo.

NIH Funding

NIH SCGE Consortium (~$190M over 6 years) identified delivery as top bottleneck. NHGRI funds dual-AAV and non-viral alternatives. ARPA-H PREPARE program targets next-gen delivery.

Who's Working On It

Sarepta Therapeutics (Elevidys micro-dystrophin), Solid Biosciences (dual-AAV), 4D Molecular Therapeutics (engineered capsids), James Wilson lab (UPenn), Guangping Gao (UMass)